BTC$61,077.00-1.94%
ETH$1,630.69-1.67%
USDT$0.9986-0.01%
BNB$562.75-1.93%
USDC$0.9998+0.00%
XRP$1.07-1.25%
SOL$68.15-1.23%
TRX$0.3284-0.77%
FIGR_HELOC$1.03-0.65%
HYPE$62.70+1.21%
DOGE$0.0761-2.84%
USDS$0.99980.00%
RAIN$0.0158-1.79%
LEO$9.39-1.26%
ZEC$412.15+0.39%
XLM$0.1821-4.08%
BTC$61,077.00-1.94%
ETH$1,630.69-1.67%
USDT$0.9986-0.01%
BNB$562.75-1.93%
USDC$0.9998+0.00%
XRP$1.07-1.25%
SOL$68.15-1.23%
TRX$0.3284-0.77%
FIGR_HELOC$1.03-0.65%
HYPE$62.70+1.21%
DOGE$0.0761-2.84%
USDS$0.99980.00%
RAIN$0.0158-1.79%
LEO$9.39-1.26%
ZEC$412.15+0.39%
XLM$0.1821-4.08%
Policy tailwinds and precision medicine breakthroughs are pushing healthcare stocks like Tempus AI and CRISPR Therapeutics into a new era of growth.
Outlook Therapeutics stock crashed 70% in premarket after the FDA rejected its wet AMD drug application, citing insufficient efficacy evidence despite previous trial successes.